Vericel (VCEL) Cash from Financing Activities (2010 - 2026)
Vericel (VCEL) reported Cash from Financing Activities of -$3.0 million for Q1 2026, down 193.15% on a YoY basis from $3.2 million in Q1 2025, and down 379.72% sequentially from $1.1 million in Q4 2025.
Vericel (VCEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Vericel (VCEL) has 17 years of Cash from Financing Activities data on file, last reported at -$3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 193.15% year-over-year to -$3.0 million; the trailing twelve-month figure through Mar 2026 stood at $893000.0 (down 95.56% YoY), and the FY2025 full-year result was $7.1 million, down 62.89% from the prior year.
- Cash from Financing Activities slipped to -$3.0 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $7.1 million in Q4 2024 to a low of -$3.0 million in Q1 2026.
- A 5-year average of $1.6 million and a median of $1.2 million in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 1886.92% in 2024 and tumbled 193.15% in 2026, its largest moves.
- Tracing VCEL's Cash from Financing Activities over 5 years: stood at $605000.0 in 2022, then jumped by 116.03% to $1.3 million in 2023, then jumped by 443.84% to $7.1 million in 2024, then slumped by 85.02% to $1.1 million in 2025, then plunged by 379.72% to -$3.0 million in 2026.
- Business Quant data shows VCEL's Cash from Financing Activities at -$3.0 million in Q1 2026, $1.1 million in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 68.63 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 9,311.16 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 238.74 Mn |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | -2.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.98 Mn |
| Mar 31, 2026 | -2.98 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |